Ublituximab Is Associated With Significant Improvement in the Multiple Sclerosis Functional Composite (MSFC): Results From the Phase 3 ULTIMATE I & II Studies
Started October 14, 2021
81
Phase 3 Results of the ULTIMATE I & II Global Studies: Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis
Started October 14, 2021
93
Study Design and Patient Demographics of the ULTIMATE Phase III Trials Evaluating Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS)
Started September 12, 2019
150
Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS)
Started September 12, 2019
127
Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Started October 11, 2018
103
Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets
Started October 27, 2017
165
Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease
Started October 26, 2017
131
Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis
Started October 26, 2017
139
Open Label Safety Study of Ublituximab for the Treatment of Acute Neuromyelitis Optica Relapses
Started September 14, 2016
265